Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy
Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy
复制标题
DOI：
10.1016/j.jhep.2013.05.017
复制
发表时间：
2013-10-01
影响因子：
25.7
通讯作者：
Hayashi, Jun
中科院分区：
文献类型：
--
作者：
Ogawa, Eiichi;Furusyo, Norihiro;Hayashi, Jun
背景与目的：贫血是TVR与聚乙二醇化干扰素、α-干扰素和病毒唑联合治疗的常见不良反应。与单独使用PegIFNα和RBV相比，TVR的发病率更高。方法：这项前瞻性多中心研究包括292名感染丙型肝炎病毒的患者(中位年龄：62岁)。所有患者都接受了12周的TVR治疗和24周的PegIFNα2b和RBV联合治疗。在抗病毒治疗中严重贫血的定义是血红蛋白(Hb)
Background & Aims: Anemia is a common adverse effect of telaprevir (TVR) in combination with pegylated interferon (PegIFN)alpha and ribavirin (RBV) therapy. It occurs at a higher incidence with the TVR relative to PegIFN alpha and RBV alone. We herein evaluate the baseline and on-treatment predictors of the development of severe anemia by chronic hepatitis C virus (HCV) patients receiving TVR-based triple therapy.Methods: This prospective, multicenter study consisted of 292 patients (median age: 62 years) infected with HCV genotype 1. All received 12 weeks of TVR in combination with 24 weeks of PegIFN alpha 2b and RBV. The definition of severe anemia during antiviral treatment is hemoglobin (Hb)